Amorphical Reports Promising Long-Term Outcomes for Crohn's Disease Treatment in Phase 2 Study Amorphical announces positive long-term results from its Phase 2 trial on Crohn's disease, validating the effectiveness of its nano-amorphous Calcium Carbonate therapy.

Amorphical Reports Promising Long-Term Outcomes for Crohn's Disease Treatment in Phase 2 Study #Israel #Crohn's_Disease #Amorphical #Nes_Ziona #Calcium_Carbonate

First Patient Enrolled in Phase 2 Trial for Innovative Therapy in Late-Stage Pancreatic Cancer Amorphical has enrolled the first patient for its Phase 2 clinical trial evaluating a novel therapy aimed at mitigating stage IV pancreatic cancer, aiming to improve patient survival rates.

First Patient Enrolled in Phase 2 Trial for Innovative Therapy in Late-Stage Pancreatic Cancer #Israel #Clinical_Trial #pancreatic_cancer #Amorphical #Nes_Ziona

Amorphical Reports Encouraging Interim Outcomes in Crohn's Disease Clinical Trial Amorphical has released positive interim results from its clinical trial for a Crohn's disease therapy, demonstrating significant patient improvement.

Amorphical Reports Encouraging Interim Outcomes in Crohn's Disease Clinical Trial #Israel #Crohn's_Disease #Amorphical #Nano-Amorphous #Nes_Ziona

Amorphical Leads the Charge in Nano-Amorphous Therapeutics with New CEO Eden Ben Amorphical boosts its innovative path in health solutions with Eden Ben as CEO, focusing on nano-amorphous mineral therapies for serious diseases.

Amorphical Leads the Charge in Nano-Amorphous Therapeutics with New CEO Eden Ben #Israel #ZION #Amorphical #Eden_Ben #Nano-Amorphous